Increasing Number of Pipeline Products Is expected To Boost Growth Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
Multiple myeloma (MM) is a clonal plasma cell malignant
neoplasm found in the soft, spongy bone marrow tissue. Plasma cells are an
important component of the immune system, aiding in the fight against various
infections and diseases. Multiple myeloma is a type of cancer characterised by
low blood counts, renal failure, hypercalcemia, immune suppression, monoclonal
gammopathy, and anaemia caused by malignant plasma cells. Furthermore, multiple
myeloma is still an incurable disease.
The global
B-cell Maturation
Antigen (BCMA) Targeted Therapies Market is expected to grow
rapidly during the forecast period, owing primarily to an increase in cancer
prevalence and the rate at which conventional therapies are failing.
Furthermore, key market players are strategically partnering
and collaborating to expand the company's product portfolio and geographical
presence.North America dominated the global market, owing to a growing number
of R&D activities, the presence of a large pharmaceutical sector, and high
adoption rates of already approved therapies. Other regions, such as Europe and
Asia-Pacific, are expected to grow rapidly as the prevalence of disorders rises
and public awareness grows.
Over time, cancer research has deviated from the
conventional approach and is now focused on the development of novel drugs that
selectively target oncogenes, reducing adverse side effects. B-cell maturation
antigen, or CD269, has been found to be highly expressed in both normal and
malignant cells, making it an ideal target antigen for the development of novel
multiple myeloma therapies.
Comments
Post a Comment